inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion
23.10.2026 16:00:00 EEST | Business Wire | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/
inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan
Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice.
The three companies will evaluate the technical, operational, regulatory and commercial feasibility of offering level 4-ready autonomous vehicles to riders through the inDrive app in Kazakhstan. Pony.ai would provide its seventh-generation (Gen-7) robotaxis, inDrive would provide the ride-hailing platform and run the service, while NVIDIA would support the project with NVIDIA AI infrastructure.
The NVIDIA Hyperion is a reference sensor and compute platform for Level 4 autonomous vehicles and robotaxis. The NVIDIA robotaxi platform combines NVIDIA Hyperion with Alpamayo Stack and Halos full-stack safety system to accelerate safe, production-ready autonomy.
inDrive and Pony.ai plan to launch robotaxis in Astana, Kazakhstan's capital, using Pony.ai's Gen-7 robotaxis. Pony.ai’s Level 4 autonomous driving technology has been validated through fully driverless commercial operations in major Chinese cities, as well as real-world deployments across Europe, the Middle East and Asia. The Gen-7 robotaxi incorporates multi-sensor fusion, system-level redundancy and fail-operational capabilities to support safe and reliable driverless operations. The launch would follow an agreement with the government of Kazakhstan.
Astana, one of Central Asia’s fastest-growing capitals, offers a promising environment for autonomous ride-hailing. With a population of approximately 1.7 million and growing demand for urban transportation, the city presents opportunities for robotaxis to complement existing mobility services and offer residents more convenient travel options. Combined with inDrive’s established presence in Kazakhstan, the initiative could provide a foundation for exploring autonomous mobility in other markets across the region. Following the initial launch in Astana, the companies will assess whether the approach could be extended to other cities in Kazakhstan as well as other countries where inDrive operates.
Arsen Tomsky, Founder and CEO of inDrive, said: "Autonomous mobility has the potential to make transportation more affordable and accessible in the cities we serve. Partnering with NVIDIA and Pony.ai, we want to understand, carefully and responsibly, how this technology could fit Kazakhstan's roads and communities - and what it could mean for riders and drivers across our markets. Kazakhstan’s forward-looking approach to regulating autonomous vehicles creates the environment to do that, and that could serve as a model for other markets. In addition, Astana is also the second-coldest capital in the world, with long winters, snow and ice. Launching here will provide an important opportunity to evaluate autonomous driving technology in challenging winter conditions. Success in Astana could offer valuable insights for expanding autonomous mobility to other locations facing similar challenges.”
“Kazakhstan represents an exciting opportunity to bring autonomous mobility to a new market in Central Asia,” said Dr. James Peng, Founder and CEO of Pony.ai, “Drawing on our experience in scaling fully driverless robotaxi operations in China and expanding into international markets, we look forward to working with inDrive and NVIDIA to explore how our proven technology can be adapted to local needs. This collaboration marks another step toward our vision of making autonomous mobility accessible to more people around the world.”
“Bringing autonomous mobility to more communities requires AI built for the complexity of real-world driving, with safety at its foundation,” said Rishi Dhall, Vice President of automotive at NVIDIA. “With NVIDIA Hyperion and the NVIDIA Halos safety system, inDrive and Pony.ai can explore a path to scalable robotaxi services in Kazakhstan, combining autonomous driving technology with a platform that connects millions of riders.”
About inDrive
inDrive is a global mobility and delivery platform. The inDrive app has been downloaded over 400 million times, and has been named the second most downloaded ride-hailing app. In addition to ride-hailing, inDrive provides an expanding list of services, including intercity transportation, delivery, and financial services. In 2023, inDrive launched New Ventures, a venture and M&A arm.
inDrive operates in over 1200 cities in 47 countries. Driven by its mission to challenge Injustice through fair choices, inDrive is committed to having a positive impact on people’s lives. It pursues this goal both through its core business, which supports local communities via a fair pricing model; and through the work of its impact programs.
About Pony AI Inc.
Pony AI Inc. is a global leader in achieving large-scale commercialization of autonomous mobility. Leveraging its vehicle-agnostic Virtual Driver technology, a full-stack autonomous driving technology that seamlessly integrates Pony.ai's proprietary software, hardware and services, Pony.ai is developing a commercially viable and sustainable business model that enables the mass production and deployment of vehicles across transportation use cases. Founded in 2016, Pony.ai has expanded its presence across China, Europe, Asia, the Middle East and other regions, ensuring widespread access to its advanced technology.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261023143469/en/
Contacts
For Media inquiries, please contact:
inDrive: press@indriver.com
Pony.ai: media@pony.ai
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 14:30:00 EEST | Press release
Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom